US-China Biotech Deal Flow Faces Geopolitical Headwinds as Washington Targets Investment Links

The Quick Take

• Cross-border biotech deals between the US and China are becoming more complex and face a modest slowdown as Washington steps up restrictions on investment and technology transfers
• ING Research senior healthcare economist warns geopolitical scrutiny will lead to 'slightly fewer deals,' though the broader trend of collaboration is expected to continue
• Regulatory hurdles are adding due-diligence costs and timeline extensions to cross-border licensing, co-development, and M&A structures

The US government's escalating restrictions on investment and technology transfers into China are now visibly affecting one of the most active cross-border deal sectors: biotechnology. SCMP's reporting, citing ING Research senior healthcare economist Diederik Stadig, confirms that deal complexity has increased materially — with companies needing to navigate overlapping regulatory frameworks including CFIUS scrutiny, Export Administration Regulations, and China's own data security and outbound investment review rules. The total number of cross-border biotech transactions is expected to decline modestly from recent peak levels, though the trend of US-China biotech collaboration is characterized as durable given mutual scientific and commercial interests.

The implications for biotech M&A and licensing markets are significant. Chinese pharmaceutical companies — including established players like BeiGene, Zai Lab, and Hengrui — have been active acquirers of US and European biotech assets, while US firms have licensed Chinese clinical-stage molecules to access faster NMPA approval pathways. Additional regulatory friction raises the transaction cost of these structures, potentially diverting deal flow toward less complex geographies — Southeast Asia, India, or European markets — for both Chinese and American biotech firms seeking cross-border expansion. Healthcare private equity funds with China-US portfolios face increased compliance burden and deal-timeline uncertainty.

Investors monitoring this space should watch for updates from CFIUS quarterly reviews and any executive orders extending restrictions to biotech and healthcare-specific investment categories beyond the current semiconductor and AI restriction focus. The macro variable is whether the US-China diplomatic backdrop — currently constructive following Iran-related diplomatic alignments — improves enough to create a regulatory carve-out for biotech distinct from the semiconductor restriction track. Any formal US-China science cooperation agreement would be the most bullish catalyst for cross-border biotech deal normalization.

Synthesized from 1 source.